サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1493385

米国のオリゴヌクレオチド合成市場規模、シェア、動向分析レポート：製品・サービス別、用途別、最終用途別、セグメント予測、2024-2030年

U.S. Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Oligonucleotides, Equipment/Synthesizer), By Application (PCR Primers, Sequencing), By End-use, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 90 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
米国のオリゴヌクレオチド合成市場規模、シェア、動向分析レポート：製品・サービス別、用途別、最終用途別、セグメント予測、2024-2030年
出版日: 2024年05月31日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国のオリゴヌクレオチド合成市場の成長と動向：

Grand View Research, Incの最新レポートによると、米国のオリゴヌクレオチド合成市場規模は2030年までに30億9,000万米ドルに達すると予測され、2024年から2030年までのCAGRは12.80%で成長すると予測されています。

分子診断の需要の高まり、新規アプリケーションの出現、心血管疾患、網膜疾患、がんなどの難治性適応症の新たな可能性に起因するオリゴヌクレオチド治療薬の需要の増加は、予測期間中にオリゴヌクレオチド合成の需要を増加させると予測されています。

COVID-19パンデミックは米国のオリゴヌクレオチド合成産業に好影響を与えました。しかし、パンデミックの間、オリゴヌクレオチド合成の需要は、製薬会社やヘルスケア専門家がオリゴヌクレオチドのより効率的な使用法を特定し、COVID-19の蔓延を抑えるためにその応用に焦点を当てたことから伸びた。例えば、Innovative Genomic Instituteは2020年に、COVID-19感染を治療するために呼吸またはネブライザーで吸入できる、エアロゾル化されたロックされた核酸修飾アンチセンスオリゴヌクレオチドを開発していると述べた。このような進歩はヘルスケア提供者の興味をそそった。したがって、パンデミックは米国市場に好影響を与えました。

さらに、企業はオリゴヌクレオチドベースの治療薬を開発するための投資を増やしています。例えば、2023年10月、GSK plcとArrowhead Pharmaceuticalsは、ジョンソン・エンド・ジョンソン傘下のJanssen Pharmaceuticals, Inc.（ヤンセン）との間で、JNJ-3989を開発・商業化する全世界での独占権をGSKに譲渡する契約を締結したと発表しました。ヤンセンは当初、2018年にアローヘッドからJNJ-3989（以前はARO-HBV）を導入しました。老舗製薬企業による同様の取り組みが、予測期間中の市場成長を促進すると予想されます。

しかし、オリゴヌクレオチド合成は、高い可能性を秘めた用途であっても、実用化には課題や問題がつきまとう。合成から高い収率を得るために最も重要なパラメータの一つは、カップリング効率のモニタリングです。平均カップリングにおけるわずかな失敗率でさえ、長い配列において劇的な影響を引き起こします。平均カップリング不良のわずかな変化は、実質的な正味の効果につながります。従って、各カスタム合成のリアルタイムモニタリングは各プラットフォームに不可欠となり、市場の成長をある程度妨げると予想されます。

米国のオリゴヌクレオチド合成市場レポート・ハイライト

  • 2023年の売上高シェアは37.34%で、サービスが製品・サービス分野を独占しました。これは、専門的なサービスに対する需要の高まりに起因します。ゲノム研究や治療への応用が複雑化するにつれて、研究者や企業はオリゴヌクレオチド配列の合成、精製、カスタマイズをアウトソーシングするようになっています。一方、オリゴヌクレオチドは予測期間中に最も速い速度で成長すると予想されています。
  • アプリケーションセグメントでは、PCRプライマーが2023年に最大の市場シェアを占めました。独自のPCRプライマーは、研究室が病原体から微量のDNAまたはRNAを検出することを可能にし、ウイルス、細菌、寄生虫感染を含む感染症の同定を支援します。一方、シークエンシングは予測期間中に最も速い速度で成長すると予測されています。
  • 最終用途に基づくと、学術研究機関が2023年に43.16％の最大収益シェアでセグメントを支配しました。これは、学術研究機関で実施される臨床研究の数が増加していることと、研究活動に対する資金が増加していることに起因しています。一方、製薬・バイオテクノロジー企業は、予測期間中に最も速いCAGRで成長すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 米国のオリゴヌクレオチド合成市場：製品とサービスのビジネス分析

  • セグメントダッシュボード
  • 米国のオリゴヌクレオチド合成市場の製品とサービスの変動分析
  • 米国のオリゴヌクレオチド合成市場規模と動向分析、製品とサービス別、2018～2030年
  • オリゴヌクレオチド
  • 機材/合成装置
  • 試薬
  • サービス
    • DNA
    • RNA

第5章 米国のオリゴヌクレオチド合成市場：用途のビジネス分析

  • セグメントダッシュボード
  • 米国のオリゴヌクレオチド合成市場の用途変動分析
  • 米国のオリゴヌクレオチド合成市場規模と動向分析、用途別、2018～2030年
  • PCRプライマー
  • PCRアッセイとパネル
  • シーケンシング
  • DNAマイクロアレイ
  • 蛍光in situハイブリダイゼーション（FISH）
  • アンチセンスオリゴヌクレオチド
  • その他の用途

第6章 米国のオリゴヌクレオチド合成市場：最終用途のビジネス分析

  • セグメントダッシュボード
  • 米国のオリゴヌクレオチド合成市場の最終用途変動分析
  • 米国のオリゴヌクレオチド合成市場規模と動向分析、最終用途別、2018～2030年
  • 学術研究機関
  • 診断ラボ
  • 製薬・バイオテクノロジー企業

第7章 競合情勢

  • 参入企業
  • 戦略マッピング
  • 企業市況分析、2023年
  • 参入企業の概要
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Danaher Corporation
    • Dharmacon Inc.
    • Agilent Technologies
    • Bio-synthesis
    • LGC Biosearch Technologies
    • Twist Bioscience
    • TriLink BioTechnologies
    • Genscript
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 4 U.S. oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. oligonucleotide synthesis market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 Participant's overview
  • Table 7 Financial performance
  • Table 8 Key companies undergoing expansions
  • Table 9 Key companies undergoing acquisitions
  • Table 10 Key companies undergoing collaborations
  • Table 11 Key companies launching new products/services
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 U.S. oligonucleotide synthesis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 U.S. oligonucleotide synthesis market driver analysis
  • Fig. 14 U.S. oligonucleotide synthesis market restraint analysis
  • Fig. 15 U.S. oligonucleotide synthesis market: Porter's analysis
  • Fig. 16 U.S. oligonucleotide synthesis market: Product & service outlook key takeaways
  • Fig. 17 U.S. oligonucleotide synthesis market: Product & service movement analysis
  • Fig. 18 Oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 DNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Column-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Array-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Column-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Array-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Short RNA oligos (<65 nt) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Long RNA oligos (>65 nt) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 CRISPR (sgRNA) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Equipment/synthesizer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 DNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Custom oligo synthesis services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 50 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 200 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Modification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Purification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Custom oligo synthesis services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 100 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Modification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Purification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. oligonucleotide synthesis market: Application movement analysis
  • Fig. 49 U.S. oligonucleotide synthesis market: Application outlook and key takeaways
  • Fig. 50 PCR primers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 PCR assays & panels market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 DNA microarrays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Fluorescence in situ hybridization (FISH) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Antisense oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Other applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 U.S. oligonucleotide synthesis market End-use outlook key takeaways
  • Fig. 58 U.S. oligonucleotide synthesis market: End-use movement analysis
  • Fig. 59 Academic research institutes market estimates and forecast, 2018 - 2030 (USD Million))
  • Fig. 60 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Key company categorization
  • Fig. 63 Company market positioning
  • Fig. 64 Market participant categorization
  • Fig. 65 Strategy framework
目次
Product Code: GVR-4-68040-290-5

U.S. Oligonucleotide Synthesis Market Growth & Trends:

The U.S. oligonucleotide synthesis market size is anticipated to reach USD 3.09 billion by 2030 and is projected to grow at a CAGR of 12.80% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising demand for molecular diagnostics, emerging novel applications, and growing demand for oligonucleotide therapeutics owing to the emerging potential for incurable indications such as cardiovascular diseases, retinal disorders, and cancer are anticipated to increase the demand for oligonucleotide synthesis over the forecast period.

The COVID-19 pandemic has had a positive impact on the U.S. oligonucleotide synthesis industry. During the pandemic, however, the demand for oligonucleotide synthesis grew as pharmaceutical companies and healthcare professionals focused on identifying more efficient usage of oligonucleotides and their application to limit the spread of COVID-19. For instance, the Innovative Genomic Institute stated in 2020 that it was developing an aerosolized, locked nucleic acid modifying antisense oligonucleotide that can be breathed or nebulized to treat COVID-19 infection. Such advances piqued the interest of healthcare providers. Hence, the pandemic has had a favorable impact on the U.S. market.

Moreover, companies have increased investments to develop oligonucleotide-based therapeutics. For instance, in October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK the exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.

However, oligonucleotide synthesis encounters challenges and problems in practical applications, even with high-potential applications. One of the most critical parameters to get a high yield from synthesis is monitoring its coupling efficiency. Even the slightest rate of failure in average coupling causes dramatic effects in long sequences. A minor change in average coupling failure leads to a substantial net effect. Thus, real-time monitoring of each custom synthesis becomes essential for every platform and, thereby, is anticipated to hamper the growth of the market to a certain extent.

U.S. Oligonucleotide Synthesis Market Report Highlights:

  • Services dominated the product & service segment with the largest revenue share of 37.34% in 2023. This is attributed to the growing demand for specialized services. As the complexity of genomic research and therapeutic applications increases, researchers & companies are turning to outsourcing for the synthesis, purification, and customization of oligonucleotide sequences. On the other hand, oligonucleotide are expected to grow at the fastest rate over the forecast period.
  • The PCR primers held the largest market share in 2023 for the application segment. Unique PCR primer allows labs to detect tiny quantities of DNA or RNA from pathogens, assisting in the identification of infectious diseases, including viral, bacterial, and parasitic infections. On the other hand, sequencing is expected to grow at the fastest rate over the forecast period.
  • Based on end use, academic research institutes dominated the segment with the largest revenue share of 43.16% in 2023. This is attributed to the increasing number of clinical studies, which are being conducted in academic institutes and the growing funding for research activities. On the other hand, pharmaceutical & biotechnology companies are anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product & Service
    • 1.2.2. Application
    • 1.2.3. End-use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
      • 3.2.1.2. High R&D spending of pharmaceutical & biotechnology companies
      • 3.2.1.3. Technological advancements in gene editing technologies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Need for advanced oligo synthesis solutions
      • 3.2.2.2. High cost associated with genomics research
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Oligonucleotide Synthesis Market: Product & Service Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Oligonucleotide Synthesis Market Product & Service Movement Analysis
  • 4.3. U.S. Oligonucleotide Synthesis Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
  • 4.4. Oligonucleotides
    • 4.4.1. Oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.1. DNA
      • 4.4.1.1.1. DNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.1.2. Column-based
      • 4.4.1.1.2.1. Column-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.1.3. Array-based
      • 4.4.1.1.3.1. Array-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2. RNA
      • 4.4.1.2.1. RNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.2. By Technology
      • 4.4.1.2.2.1. Column-based
      • 4.4.1.2.2.1.1. Column-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.2.2. Array-based
      • 4.4.1.2.2.2.1. Array-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.3. By Type
      • 4.4.1.2.3.1. Short RNA Oligos (<65 nt)
      • 4.4.1.2.3.1.1. Short RNA oligos (<65nt) market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.3.2. Long RNA Oligos (>65 nt)
      • 4.4.1.2.3.2.1. Long RNA oligos (>65 nt) market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.3.3. CRISPR (sgRNA)
      • 4.4.1.2.3.3.1. CRISPR (sgRNA) market estimates and forecast, 2018 - 2030 (USD Million
  • 4.5. Equipment/Synthesizer
    • 4.5.1. Equipment/synthesizer market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.6. Reagents
    • 4.6.1. Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.7. Services
    • 4.7.1. Services market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.7.2. DNA
      • 4.7.2.1. DNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2. Custom Oligo Synthesis Services
      • 4.7.2.2.1. 25 nmol
      • 4.7.2.2.1.1. 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.2. 50 nmol
      • 4.7.2.2.2.1. 50 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.3. 200 nmol
      • 4.7.2.2.3.1. 200 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.4. 1000 nmol
      • 4.7.2.2.4.1. 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.5. 10000 nmol
      • 4.7.2.2.5.1. 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.3. Modification Services
      • 4.7.2.3.1. Modification services market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.4. Purification Services
      • 4.7.2.4.1. Purification services market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.7.3. RNA
      • 4.7.3.1. RNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2. Custom Oligo Synthesis Services
      • 4.7.3.2.1. 25 nmol
      • 4.7.3.2.1.1. 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2.2. 100 nmol
      • 4.7.3.2.2.1. 100 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2.3. 1000 nmol
      • 4.7.3.2.3.1. 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2.4. 10000 nmol
      • 4.7.3.2.4.1. 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.3. Modification Services
      • 4.7.3.3.1. Modification services market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.4. Purification Services
      • 4.7.3.4.1. Purification services market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Oligonucleotide Synthesis Market: Application Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Oligonucleotide Synthesis Market Application Movement Analysis
  • 5.3. U.S. Oligonucleotide Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. PCR Primer
    • 5.4.1. PCR primer market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. PCR Assay & Panel
    • 5.5.1. PCR assay & panel market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Sequencing
    • 5.6.1. Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7. DNA Microarrays
    • 5.7.1. DNA microarrays market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.8. Fluorescence In Situ Hybridization (FISH)
    • 5.8.1. Fluorescence in situ hybridization (FISH) market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.9. Antisense Oligonucleotides
    • 5.9.1. Antisense oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.10. Other Applications
    • 5.10.1. Other applications market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Oligonucleotide Synthesis Market: End-use Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Oligonucleotide Synthesis Market End-use Movement Analysis
  • 6.3. U.S. Oligonucleotide Synthesis Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 6.4. Academic Research Institutes
    • 6.4.1. Academic research institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5. Diagnostic Laboratories
    • 6.5.1. Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6. Pharmaceutical & Biotechnology Companies
    • 6.6.1. Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2023
  • 7.4. Participant's Overview
    • 7.4.1. Thermo Fisher Scientific, Inc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product & service benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Merck KGaA
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product & service benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Danaher Corporation
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product & service benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Dharmacon Inc.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product & service benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Agilent Technologies
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product & service benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Bio-synthesis
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product & service benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. LGC Biosearch Technologies
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product & service benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Twist Bioscience
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product & service benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. TriLink BioTechnologies
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product & service benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Genscript
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product & service benchmarking
      • 7.4.10.4. Strategic initiatives